title: Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al.
authors.affiliation: Massachusetts General Hospital, Boston, MA.
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Hughes
authors.forename: Lauren A
authors.initials: LA
authors.lastname: Schnaper
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Bellon
authors.forename: Constance T
authors.initials: CT
authors.lastname: Cirrincione
authors.forename: Donald A
authors.initials: DA
authors.lastname: Berry
authors.forename: Beryl
authors.initials: B
authors.lastname: McCormick
authors.forename: Hyman B
authors.initials: HB
authors.lastname: Muss
authors.forename: Barbara L
authors.initials: BL
authors.lastname: Smith
authors.forename: Clifford A
authors.initials: CA
authors.lastname: Hudis
authors.forename: Eric P
authors.initials: EP
authors.lastname: Winer
authors.forename: William C
authors.initials: WC
authors.lastname: Wood
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D011960:Receptors, Estrogen / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D013629:Tamoxifen